Regulatory issues in aging pharmacology

9Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

Abstract

Many current drugs increase the average lifespan by preventing fatal diseases or by slowing down the progressive degenerative diseases that increase mortality. The existing strategies and guidelines for the development and regulatory approval of new drugs are designed for such compounds. Rapid advances in understanding molecular mechanisms of aging make it possible to envisage future drugs that extend the lifespan by regulating aging mechanism outside of disease pathways. Strategies for development and regulatory approval of such drugs remain to be defined. Since the drug candidates will be given to healthy, elderly subjects, safety requirements will be extremely high. Clinical studies of many years' duration will be necessary to prove changes in longevity. These time intervals may exceed those of patent protection and thus minimize commercial incentives. Despite these challenges, two broadly defined pathways are feasible. First, it may be possible to obtain public funding for studies with voluntary participation of humans consuming existing drugs or natural compounds in the 'expected to be safe' category. Second, the development of novel drugs may proceed on the basis of well-defined biomarkers of aging that can serve as surrogate end points in clinical studies. The emerging approaches will prompt the regulatory agencies into taking the first steps towards regulatory guidance. © 2006 The Authors Journal compilation © Blackwell Publishing Ltd/Anatomical Society of Great Britain and Ireland 2006.

References Powered by Scopus

Mitochondria, oxidants, and aging

3734Citations
N/AReaders
Get full text

Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase

1767Citations
N/AReaders
Get full text

IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice

1725Citations
N/AReaders
Get full text

Cited by Powered by Scopus

N-glycomic changes in serum proteins during human aging

98Citations
N/AReaders
Get full text

Compounds that confer thermal stress resistance and extended lifespan

88Citations
N/AReaders
Get full text

Classifying aging as a disease in the context of ICD-11

56Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Hefti, F. F., & Bales, R. (2006). Regulatory issues in aging pharmacology. Aging Cell, 5(1), 3–8. https://doi.org/10.1111/j.1474-9726.2006.00193.x

Readers over time

‘13‘19‘2002468

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 2

67%

Professor / Associate Prof. 1

33%

Readers' Discipline

Tooltip

Agricultural and Biological Sciences 1

33%

Medicine and Dentistry 1

33%

Psychology 1

33%

Save time finding and organizing research with Mendeley

Sign up for free
0